Botulinum toxin treatment of lateral axial dystonia in Parkinsonism

Movement Disorders

Volumn 22, Issue 14, 2007, Pages 2097-2103

  Bonanni, Laura ^a   Thomas, Astrid ^a   Varanese, Sara ^a   Scorrano, Vincenzo ^a   Onofrj, Marco ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Botulinum toxin; Lateral axial dystonia; Parkinson's disease; Parkinsonism

Indexed keywords

ANTIPARKINSON AGENT; BOTULINUM TOXIN A; CLOZAPINE; LEVODOPA; PLACEBO; TRIHEXYPHENIDYL;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DAYTIME SOMNOLENCE; DISORIENTATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; FEMALE; GONIOMETRY; HALLUCINATION; HUMAN; HYPOTENSION; LATERAL AXIAL DYSTONIA; MAJOR CLINICAL STUDY; MALE; PARKINSONISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TREATMENT RESPONSE; VIDEORECORDING;

AGED; AGED, 80 AND OVER; ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS; COHORT STUDIES; CROSS-OVER STUDIES; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; DYSTONIA; FEMALE; HUMANS; MALE; PAIN MEASUREMENT; PARKINSON DISEASE;

EID: 37549070697     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21694     Document Type: Article

References (24)

1. Ekbom K, Lindholm H, Ljungberg L. New dystonic syndrome associated to butyrophenone therapy. Z Neurol 1972;202:94-103.
2. Fichtner CG. Pleurothotonus and the Pisa syndrome. Biol Psychiatry 1992;31:534.
3. Comella CL, Shannon KM, Jaglin J. Extensor truncal dystonia: successful treatment with botulinum toxin injections. Mov Disord 1998;13:552-555.
4. Suzuki T, Matsuzada H. Drug induced Pisa syndrome (Pleurothotonus). Epidemiology and management. CNS Drugs 2002;16:165-174.
5. Cossu G, Melis M, Melis G, Maccioni E, Putzu V, Catte O, Putzu PF. Reversible Pisa syndrome (pleurothotonus) due to the cholinesterase inhibitor galantamine: case report. Mov Disord 2004;19:1243-1244.
6. Onofrj M, Thomas A. Severe worsening of parkinsonism in Lewy body dementia due to donepezil. Neurology 2003;61:1452.
7. Davidson M, Powchilk P, Davis KL. Pisa syndrome in Alzheimer's disease. Biol Psychiatry 1988;23:209-214.
8. Patel S, Tariot PN, Hamil RW. Pisa syndrome without neuroleptic exposure in a patient with dementia of the Alzheimer's type. J Geriatr Psychiatry Neurol 1991;4:48-51.
9. Colosimo C. Pisa syndrome in a patient with multiple system atrophy. Mov Disord 1998;13:607-609.
10. Harada KI. Pisa syndrome without neuroleptic exposure in a patient with Parkinson's disease: a case report. Mov Disord 2006;21:2264.
11. Gambarin M. Pisa syndrome without neuroleptic exposure in a patient with Parkinson's disease: a case report. Mov Disord 2006;21:2264-2265.
12. Yokochi F. Lateral flexion in Parkinson's disease and Pisa syndrome. J Neurol 2006;253 (Suppl 7):VII/17-VII/20.
13. Quirk JA, Sheean GL, Marsden CD, Lees AJ. Treatment of non-occupational limb and trunk dystonia with botulinum toxin. Mov Disord 1996;11:377-383.
14. Lieberman J, Lesser M, Johns C, Pollack S, Saltz B, Kane J. Pharmacologic studies of tardive dyskinesia. J Clin Psychopharmacol 1988;8 (Suppl 4):57S-63S.
15. Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology 1988;38:391-394.
16. Lamberti JS, Bellnier T. Clozapine and tardive dystonia. J Nerv Ment Dis 1993;181:137-138.
17. Pondal M, Del Ser T, Bermejo F. Anticholinergics and dementia in patients with Parkinson's disease. J Neurol 1996;243:543-546.
18. Cannas A, Solla P, Floris G, Borghero G, Tacconi P, Spissu A. Reversibile Pisa syndrome in Parkinson's disease during treatment with pergolide: a case report. Clin Neuropharmacol 2005;28:252.
19. Thomas A, Bonanni L, Di Iorio A, Varanese S, Anzellotti F, D'Andreagiovanni A, Stocchi F, Onofrj M. End-of-dose deterioration in non ergolinic dopamine agonist monotherapy of Parkinson's disease J Neurol 2006;253:1633-1639.
20. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997;277:925-926.
21. Moher D, Schulz KF, Altman DG, for the CONSORT Group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001;357:1191-1194.
22. Rosales RL, Bigalke H, Dressier D. Pharmacology of botulinum toxin: differences between type A preparations. Eur J Neurol 2006;13 (Suppl 1):2-10.
23. Fahn S. Assessment of the primary dystonias. In: Munsat TL, editor. Quantification of neurologic deficit. Boston: Butterworths; 1989. p. 241-270.
24. Downie WW, Leatham PA, Rhind VM, Wright V, Branco JA, Anderson JA. Studies with pain rating scales. Ann Rheum Dis 1978;37:378-381.